10th May 2018
- 0 comments
An East Midlands life sciences company which develops synthetic alternatives to antibodies has closed a £1.5m Series A funding round supported by Mercia Fund Managers and a number of private investors.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.